Erratum to: Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression (Neuropsychopharmacology, (2017), 42, 13, (2482-2492), 10.1038/npp.2017.94);Dose-related effects of adjunctive ketamine in taiwanese patients with treatment-resistant depression

Neuropsychopharmacology

Volumn 42, Issue 13, 2017, Pages 2482-2492

  Su, Tung Ping ^a,b   Chen, Mu Hong ^a,b   Li, Cheng Ta ^a,b   Lin, Wei Chen ^a,b   Hong, Chen Jee ^a,b   Gueorguieva, Ralitza ^c,d   Tu, Pei Chi ^a,b   Bai, Ya Mei ^a,b   Cheng, Chih Ming ^b   Krystal, John H ^d,e,f  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c YALE UNIVERSITY   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e YALE NEW HAVEN HOSPITAL   (United States)

^f VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; KETAMINE; NORKETAMINE; PLACEBO; UNCLASSIFIED DRUG; ANTIDEPRESSANT AGENT; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN;

ADULT; ALLELE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CLINICAL OUTCOME; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; GENOTYPE; HAMILTON DEPRESSION RATING SCALE; HEMODYNAMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TAIWANESE; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFECT; GENETIC POLYMORPHISM; GENETICS; HEART RATE; MAJOR DEPRESSION; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; TAIWAN; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; KETAMINE; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; TAIWAN; TREATMENT OUTCOME;

EID: 85033576477     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/s41386-018-0253-z     Document Type: Erratum

References (34)

1. Aan Het Rot M, Zarate CA Jr, Charney DS, Mathew SJ. (2012). Ketamine for depression: where do we go from here? Biol Psychiatry 72: 537-547.
2. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. (2000). Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47: 351-354.
3. Chekroud AM, Gueorguieva R, Krumholz HM, Trivedi MH, Krystal JH, McCarthy G. (2017). Reevaluating the efficacy and predictability of antidepressant treatments: a symptom clustering approach. JAMA Psychiatry 74: 370-378.
4. Chen ZY, Patel PD, Sant G, Meng CX, Teng KK, Hempstead BL, et al. (2004). Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-Type BDNF in neurosecretory cells and cortical neurons. J Neurosci 24: 4401-4411.
5. Choi MJ, Kang RH, Lim SW, Oh KS, Lee MS. (2006). Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. Brain Res 1118: 176-182.
6. Feinberg I, Campbell IG. (1993). Ketamine administration during waking increases delta EEG intensity in rat sleep. Neuropsychopharmacology 9: 41-48.
7. Feinberg I, Campbell IG. (1995). Stimulation of NREM delta EEG by ketamine administration during waking: demonstration of dose dependence. Neuropsychopharmacology 12: 89-90.
8. Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ. (2009). What did STAR D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv 60: 1439-1445.
9. Hamilton M. (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
10. Hedlund JL, Vieweg BW. (1980). The Brief Psychiatric Rating Scale (BPRS): a comprehensive review. J Operational Psychiatry 11: 48-64.
11. Hu YD, Xiang YT, Fang JX, Zu S, Sha S, Shi H, et al. (2016). Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. Psychol Med 46: 623-635.
12. Hustveit O, Maurset A, Oye I. (1995). Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol 77: 355-359.
13. Itoh K, Hashimoto K, Kumakiri C, Shimizu E, Iyo M. (2004). Association between brain-derived neurotrophic factor 196 G/A polymorphism and personality traits in healthy subjects. Am J Med Genet B Neuropsychiatr Genet 124B: 61-63.
14. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. (2008). Initial severity and antidepressant benefits: a meta-Analysis of data submitted to the Food and Drug Administration. PLoS Med 5: e45.
15. Kishimoto T, Chawla JM, Hagi K, Zarate CA, Kane JM, Bauer M, et al. (2016). Single-dose infusion ketamine and non-ketamine N-methyl-d-Aspartate receptor antagonists for unipolar and bipolar depression: a meta-Analysis of efficacy, safety and time trajectories. Psychol Med 46: 1459-1472.
16. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51: 199-214.
17. Krystal JH, Perry EB Jr, Gueorguieva R, Belger A, Madonick SH, Abi-Dargham A, et al. (2005). Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry 62: 985-994.
18. Krystal JH, Sanacora G, Duman RS. (2013). Rapid-Acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry 73: 1133-1141.
19. Laje G, Lally N, Mathews D, Brutsche N, Chemerinski A, Akula N, et al. (2012). Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol Psychiatry 72: e27-e28.
20. Li CT, Chen MH, Lin WC, Hong CJ, Yang BH, Liu RS, et al. (2016). The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: A randomized controlled study. Hum Brain Mapp 37: 1080-1090.
21. Liu RJ, Lee FS, Li XY, Bambico F, Duman RS, Aghajanian GK. (2012). Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol Psychiatry 71: 996-1005.
22. Overall JE, Gorham DR. (1962). The brief psychiatric rating scale. Psychol Rep 10: 799-812.
23. Pennybaker SJ, Niciu MJ, Luckenbaugh DA, Zarate CA. (2017). Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion. J Affect Disord 208: 560-566.
24. Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, et al. (2004). Sequenced treatment alternatives to relieve depression (STARD): rationale and design. Control Clin Trials 25: 119-142.
25. Saligan LN, Luckenbaugh DA, Slonena EE, Machado-Vieira R, Zarate CA Jr. (2016). An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder. J Affect Disord 194: 115-119.
26. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. (1998). The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(Suppl 20): 22-33 quiz 34-57.
27. Simon GE, Revicki D, VonKorff M. (1993). Telephone assessment of depression severity. J Psychiatr Res 27: 247-252.
28. Singh JB, Fedgchin M, Daly E, Xi L, Melman C, De Bruecker G, et al. (2015). Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebocontrolled study. Biol Psychiatry 80: 424-431.
29. Vande Voort JL, Ballard ED, Luckenbaugh DA, Bernert RA, Richards EM, Niciu MJ, et al. (2016). Antisuicidal response following ketamine infusion is associated with decreased nighttime wakefulness in major depressive disorder and bipolar disorder. J Clin Psychiatry (doi: 10.4088/JCP.15m10440; e-pub ahead of print
30. Xu G, Lin K, Rao D, Dang Y, Ouyang H, Mai G, et al. (2012). Brainderived neurotrophic factor gene polymorphism (Val66Met) and the early response to antidepressant in Chinese Han population. Psychiatr Genet 22: 214-215.
31. Xu Y, Hackett M, Carter G, Loo C, Galvez V, Glozier N, et al. (2016). Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-Analysis. Int J Neuropsychopharmacol (doi: 10.1093/ijnp/pyv124; e-pub ahead of print
32. Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, et al. (2016). NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 533: 481-486.
33. Zarate CA Jr, Brutsche N, Laje G, Luckenbaugh DA, Venkata SL, Ramamoorthy A, et al. (2012). Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry 72: 331-338.
34. Zhao X, Venkata SL, Moaddel R, Luckenbaugh DA, Brutsche NE, Ibrahim L, et al. (2012). Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression. Br J Clin Pharmacol 74: 304-314.